SFM
ORIC icon

Sphera Funds Management’s Oric Pharmaceuticals ORIC Stock Holding History

Sphera Funds Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08M Buy
+100,000
New +$907K 0.14% 97

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sphera Funds Management's ORIC Position: Q2 2026 in Review

Sphera Funds Management increased its Oric Pharmaceuticals (ORIC) stake by 40% in Q2 2026, buying an estimated $1.95M and bringing the position to 752,983 shares worth $8.15M. The position accounts for 1.06% of the portfolio, ranked #26.

Sphera Funds Management first reported a position in ORIC in Q4 2020 and has held it in 11 quarters since. The position peaked at $8.22M in Q4 2025. 181 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Sphera Funds Management held 752,983 shares of Oric Pharmaceuticals worth $8.15M as of Q2 2026.
  • Sphera Funds Management bought 215,355 Oric Pharmaceuticals shares in Q2 2026, an estimated $1.95M.
  • Oric Pharmaceuticals made up 1.06% of Sphera Funds Management's portfolio in Q2 2026, its #26 holding.
  • Sphera Funds Management first reported a position in Oric Pharmaceuticals in Q4 2020 and has held it in 11 quarters since.
  • Sphera Funds Management's Oric Pharmaceuticals position peaked at $8.22M in Q4 2025.
  • 181 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Sphera Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.